To assess the safety and tolerability of multiple ascending doses AZD1152 in patients with AML by assessment of AEs, vital signs, ECG parameters, clinical chemistry, haematology (including clotting parameters) and urinalysis. Assessed at each visit [clinicaltrials_resource:3ef6d891907c57b14cbc88828df8c8a6]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
To assess the safety and tolerability of multiple ascending doses AZD1152 in patients with AML by assessment of AEs, vital signs, ECG parameters, clinical chemistry, haematology (including clotting parameters) and urinalysis. Assessed at each visit [clinicaltrials_resource:3ef6d891907c57b14cbc88828df8c8a6]
Bio2RDF identifier
3ef6d891907c57b14cbc88828df8c8a6
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:3ef6d891907c57b14cbc88828df8c8a6
measure [clinicaltrials_vocabulary:measure]
To assess the safety and toler ...... ng parameters) and urinalysis.
time frame [clinicaltrials_vocabulary:time-frame]
Assessed at each visit
identifier
clinicaltrials_resource:3ef6d891907c57b14cbc88828df8c8a6
title
To assess the safety and toler ...... alysis. Assessed at each visit
@en
type
label
To assess the safety and toler ...... 6d891907c57b14cbc88828df8c8a6]
@en